FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction
The U.S. Food and Drug Administration has approved Lipfendra (enlicitide), an oral medication designed to lower LDL cholesterol. This approval marks the first time an oral PCSK9 inhibitor has received authorization for use in adults with high cholesterol.
Advertisement
WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9).
Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!